HGH Peptides Research Guide: CJC-1295, Ipamorelin & Growth Hormone Secretagogues -

All peptides discussed on this page are sold by Webber Science for in vitro research purposes only. They are not intended for human or veterinary use. This content is provided for informational purposes and does not constitute medical advice.

Introduction

Growth hormone (GH) is a 191-amino-acid polypeptide secreted by the anterior pituitary in pulsatile fashion. Its secretion is regulated by two hypothalamic hormones: growth hormone-releasing hormone (GHRH), which stimulates release, and somatostatin, which inhibits it. Ghrelin — produced in the stomach — provides a third stimulatory input via the growth hormone secretagogue receptor (GHSR).

Recombinant human growth hormone (rhGH) has been used clinically for decades, but its parenteral administration produces supraphysiological, non-pulsatile GH elevation that diverges from normal physiology. This has motivated the development of growth hormone secretagogues (GHS) — peptides that stimulate the pituitary to release endogenous GH in a more physiological pattern.

This guide covers three of the most researched GHRH analogues and secretagogues available for Canadian laboratory research: CJC-1295 (with and without DAC), Ipamorelin, and Tesamorelin. We review the distinct mechanisms, comparative pharmacology, and relevant preclinical and clinical evidence for each.

Growth Hormone Physiology: A Brief Review

Understanding how secretagogues work requires familiarity with the hypothalamic-pituitary-GH axis:

The GHRH–GH–IGF-1 Axis

1. GHRH release — The hypothalamus secretes GHRH in pulses (every ~3 hours in humans), which binds GHRH receptors on somatotrophs in the anterior pituitary.

2. GH secretion — Somatotrophs respond by synthesizing and releasing GH in a pulsatile manner. The amplitude (not frequency) of pulses is modulated by GHRH, ghrelin, sex steroids, and sleep.

3. Somatostatin inhibition — Somatostatin reduces both the frequency and amplitude of GH pulses. It is the primary brake on GH secretion.

4. IGF-1 feedback — GH stimulates hepatic IGF-1 production, which provides negative feedback on both the hypothalamus (reducing GHRH) and the pituitary (reducing GH sensitivity to GHRH).

5. Ghrelin input — Ghrelin from the stomach binds GHSR on somatotrophs, potentiate GHRH-stimulated GH release and can increase pulse amplitude independently.

Why Pulsatility Matters

GH’s biological effects are concentration- AND pattern-dependent. Pulsatile GH signalling preferentially activates hepatic IGF-1 and lipolysis, while continuous (non-pulsatile) exposure upregulates hepatic enzymes that convert T4 to T3 and can promote insulin resistance. This is why secretagogues that preserve pulsatility are considered a more physiological approach than exogenous rhGH.

CJC-1295

Background and Structure

CJC-1295 is a synthetic analogue of GHRH (1–29), originally developed by ConjuChem Biotechnologies. Two formulations exist:

CJC-1295 without DAC (also called Modified GRF 1-29 or Sermorelin analogue) — A 29-amino-acid peptide with four amino acid substitutions (D-Ala₂, Gln⁸, Ala¹⁵, Leu²⁷) that increase resistance to proteolytic degradation by dipeptidyl peptidase IV (DPP-IV). Half-life: ~30 minutes.
CJC-1295 with DAC (Drug Affinity Complex) — Adds a lysine-linked maleimidopropionic acid moiety at the C-terminus that covalently binds serum albumin. This dramatically extends the half-life to approximately 5–8 days.

Mechanism of Action

CJC-1295 binds the GHRH receptor on anterior pituitary somatotrophs with similar affinity to native GHRH but with:

DPP-IV resistance — The amino acid substitutions prevent rapid enzymatic cleavage that destroys native GHRH within minutes.
Albumin binding (DAC version) — Covalent albumin binding creates a long-acting depot effect, maintaining GHRH receptor stimulation across multiple natural GH pulse windows.

The result is amplified GH pulse amplitude while preserving the natural pulsatile release pattern, because GHRH receptor activation must still coincide with low somatostatin tone for GH release to occur.

Preclinical and Clinical Evidence

Phase I/II trials (ConjuChem): Demonstrated 2- to 10-fold increases in GH peak levels and sustained IGF-1 elevations over 13 days after a single dose (DAC version). Healthy volunteers showed dose-dependent IGF-1 increases without significant tolerance.
Half-life comparison: CJC-1295 without DAC has a subcutaneous half-life of ~30 min, requiring more frequent administration in research protocols. CJC-1295 with DAC provides sustained IGF-1 elevation over 1–2 weeks.
No cortisol or prolactin elevation: Unlike some GHS, CJC-1295 selectively stimulates GH without elevating ACTH, cortisol, or prolactin in studied models.

📘 Comprehensive guide: CJC-1295 Complete Guide for Canadian Researchers

🛒 Source for your lab: CJC-1295 No DAC — Webber Science | CJC-1295 with DAC — Webber Science

Ipamorelin

Background and Structure

Ipamorelin is a synthetic pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH₂) that acts as a selective growth hormone secretagogue receptor (GHSR) agonist. It was the first in the “non-peptidyl” class of secretagogues, though it retains a peptide backbone.

Mechanism of Action

Ipamorelin mimics ghrelin’s stimulation of GH release by binding GHSR-1a (the active form of the ghrelin receptor) on somatotrophs:

GHSR-1a agonism — Potentiates GHRH-stimulated GH release and can independently trigger GH pulses, particularly during periods of low somatostatin tone.
High selectivity — Unlike ghrelin and earlier GHS (e.g., GHRP-6, GHRP-2), ipamorelin does not significantly stimulate ACTH, cortisol, prolactin, or appetite (orexic) pathways at research-relevant concentrations.
Synergy with GHRH analogues — GHSR agonism and GHRH receptor agonism act synergistically; co-administration of ipamorelin with CJC-1295 produces greater GH release than either alone.

Preclinical and Clinical Evidence

Preclinical selectivity: In swine models, ipamorelin dose-dependently increased GH levels without elevating cortisol, prolactin, LH, FSH, or TSH — a selectivity profile superior to GHRP-2 and GHRP-6.
Gastric motility: Low-dose ipamorelin accelerates gastric emptying via GHSR-1a on vagal afferents, a property shared with ghrelin but at doses below those needed for significant GH release.
Clinical: Ipamorelin reached Phase II trials for postoperative ileus but was not advanced further. No current clinical trials are active.

CJC-1295 + Ipamorelin: The Research Combination

The combination of a GHRH analogue (CJC-1295) and a GHSR agonist (Ipamorelin) is one of the most commonly investigated secretagogue pairings in the research community. The rationale is mechanistically sound:

CJC-1295 increases the amplitude of GH pulses by making GHRH stimulation more durable.
Ipamorelin amplifies pulse amplitude via a different receptor (GHSR) and can trigger additional pulses.
The combination produces synergistic GH release — not merely additive — because both receptors must be co-activated for maximal somatotroph response.

This mirrors the physiological interplay between the body’s native GHRH and ghrelin systems.

🛒 Source for your lab: Ipamorelin — Webber Science

Tesamorelin

Background and Structure

Tesamorelin is a synthetic GHRH analogue with a trans-3-hexenoic acid group at the N-terminus (position 1), which increases its resistance to enzymatic degradation by increasing the peptide’s affinity for serum proteins. It is the only GHRH analogue to receive FDA approval (as Egrifta, 2010) for the treatment of HIV-associated lipodystrophy.

Mechanism of Action

Tesamorelin’s mechanism is functionally identical to native GHRH:

GHRH receptor agonism — Binds and activates GHRH receptors on pituitary somatotrophs, stimulating GH synthesis and release.
Pulsatile GH preservation — Like other GHRH analogues, tesamorelin amplifies natural GH pulse amplitude without disrupting pulsatility.
Trans-3-hexenoic acid stabilization — The lipid modification extends half-life to approximately 2–3 hours (subcutaneous), significantly longer than native GHRH (~7 min) but shorter than CJC-1295 with DAC.

Clinical Evidence

Tesamorelin has the most robust clinical dataset of any GHRH analogue:

HIV-associated lipodystrophy: Two pivotal Phase III trials demonstrated significant reductions in visceral adipose tissue (VAT) — the primary endpoint — over 26 weeks. Effects were sustained through 52 weeks in extension studies.
Metabolic parameters: Consistent improvements in triglycerides, waist circumference, and patient-reported outcomes regarding body image.
GH/IGF-1 levels: Produced 2- to 4-fold increases in GH peaks and sustained IGF-1 elevations within the normal reference range.
Safety: Generally well tolerated; mild injection-site reactions and transient hyperglycaemia were the most common adverse events.

Key Distinction from Other GHS

Unlike ipamorelin and CJC-1295, tesamorelin’s clinical development focused specifically on visceral adipose tissue reduction rather than general GH augmentation. The clinical data specifically demonstrate greater relative reduction in visceral fat versus subcutaneous fat, making it relevant for researchers studying depot-specific adipose biology.

🛒 Source for your lab: Tesamorelin — Webber Science

Comparative Pharmacology: CJC-1295 vs. Ipamorelin vs. Tesamorelin

Understanding the differences between these secretagogues is essential for selecting the right tool for your research:

|—|—|—|—|—|

| Half-life | ~30 min | ~5–8 days | ~2 h | ~2–3 h |

| Cortisol elevation | No | No | No* | No |

| Appetite effect | No | No | Minimal | No |

Ipamorelin does not elevate cortisol at typical research doses; supraphysiological concentrations may produce marginal ACTH elevation in some models.

Selecting the Right Secretagogue

Studying GHRH pathway specificity → CJC-1295 without DAC (short-acting, clean GHRH-R agonism)
Studying prolonged IGF-1 elevation → CJC-1295 with DAC (albumin-bound, sustained release)
Studying ghrelin/GHSR pathway selectivity → Ipamorelin (clean GHSR-1a agonism without ACTH/prolactin effects)
Studying depot-specific adipose biology → Tesamorelin (clinical evidence for VAT reduction)
Studying synergistic GH release → CJC-1295 + Ipamorelin combination (GHRH-R + GHSR-1a co-activation)

Research Protocol Considerations

Dosing Frequency

CJC-1295 without DAC — Short half-life requires 1–3× daily administration in most animal models.
CJC-1295 with DAC — Long half-life supports once-weekly or biweekly dosing.
Ipamorelin — Intermediate half-life supports 1–3× daily dosing.
Tesamorelin — Clinical studies used once-daily subcutaneous injection.

Pulsatility and Administration Timing

When studying GHRH analogues, timing matters. GH pulses are entrained to sleep, exercise, and fasting states. Administering secretagogues at times of naturally low somatostatin tone (e.g., early sleep, post-exercise) amplifies the GH response. Conversely, administration during high somatostatin periods produces blunted releases — a useful negative control.

Monitoring Endpoints

Key biomarkers in GH secretagogue research include:

Serum GH — Pulsatile pattern, measured via serial sampling or 24-hour integrated concentration.
IGF-1 — Reflects cumulative GH exposure over the preceding 12–24 hours.
IGFBP-3 — GH-dependent binding protein; useful as a secondary marker.
Body composition — DXA, MRI (VAT/SAT), or ultrasound in appropriate models.
Fasting glucose and insulin — GH can induce transient insulin resistance, relevant to safety monitoring.

Sourcing GH Secretagogues in Canada

Canadian research teams should consider:

1. Regulatory framework — Tesamorelin has Health Canada Notice of Compliance (under the brand Egrifta) for HIV-associated lipodystrophy, but Webber Science supplies it for research purposes only. CJC-1295 and Ipamorelin have no Health Canada drug approval.

2. Purity and identity — Request certificates of analysis confirming ≥98% peptide purity and identity (via mass spectrometry).

3. Lyophilized handling — Reconstitute with bacteriostatic water according to COA instructions; avoid repeated freeze-thaw cycles.

4. Domestic availability — Sourcing from Canadian suppliers eliminates customs delays and simplifies cold-chain logistics.

FAQ

What is the difference between CJC-1295 with DAC and without DAC?

The DAC (Drug Affinity Complex) is a maleimidopropionic acid group covalently linked to a lysine residue at the C-terminus of CJC-1295. This group binds serum albumin, extending the peptide’s half-life from ~30 minutes (without DAC) to ~5–8 days (with DAC). Functionally, CJC-1295 without DAC produces more physiological, short-duration GH pulse amplification, while CJC-1295 with DAC provides sustained IGF-1 elevation suitable for less frequent dosing.

Is ipamorelin better than GHRP-2 or GHRP-6?

“Better” depends on the research question. Ipamorelin is more selective — it stimulates GH release via GHSR-1a without significantly elevating cortisol, prolactin, or appetite. GHRP-2 and GHRP-6 have broader effects, including ACTH/cortisol stimulation (GHRP-2) and strong appetite stimulation (GHRP-6). For researchers who want isolated GHSR-1a agonism, ipamorelin is the preferred tool.

Can CJC-1295 and ipamorelin be used together in research?

Yes. The combination of a GHRH analogue (CJC-1295) and a GHSR agonist (ipamorelin) is well-supported by mechanistic data. GHRH and ghrelin receptor agonism act synergistically on somatotrophs — both receptors must be co-activated for maximal GH release. This is a standard research paradigm in secretagogue studies.

Does tesamorelin only reduce visceral fat?

The strongest clinical evidence for tesamorelin specifically demonstrates visceral adipose tissue (VAT) reduction. In HIV-associated lipodystrophy trials, the VAT-to-SAT reduction ratio favoured visceral fat loss. However, tesamorelin’s mechanism (GHRH agonism → GH release → IGF-1 elevation → lipolysis) is not depot-specific per se. The apparent VAT selectivity likely reflects GH’s preferential effect on visceral adipocytes, which have higher GH receptor density and lipolytic responsiveness.

What is the research relevance of GH pulsatility?

Pulsatile GH secretion produces different downstream effects than continuous elevation. Pulsatile signalling preferentially activates hepatic STAT5b (driving IGF-1 production and longitudinal bone growth) while minimizing hepatic insulin resistance. Continuous GH elevation upregulates different gene programmes, including those that promote gluconeogenesis and lipogenesis. Secretagogues that preserve pulsatility — unlike exogenous rhGH — are therefore more physiologically relevant for many research applications.

Are GH secretagogues legal for research in Canada?

Yes. GH secretagogues including CJC-1295, Ipamorelin, and Tesamorelin are legal to purchase for in vitro and preclinical laboratory research in Canada. They are not approved as dietary supplements or therapeutic drugs (with the exception of tesamorelin, which has an NOC from Health Canada for a specific clinical indication). Researchers must ensure compliance with their institution’s research ethics and procurement policies.

Browse HGH Peptides and Secretagogues

Ready to source growth hormone secretagogues for your research? Explore the Webber Science catalogue:

All products are for research purposes only. Not for human or veterinary use.

References

Teichman, S.L. et al. (2006). “Prolonged increase in GH/IGF-1 axis with CJC-1295.” *Journal of Clinical Endocrinology & Metabolism*, 91(10), 3861–3868.
Raun, K. et al. (1998). “Ipamorelin, the first selective growth hormone secretagogue.” *European Journal of Endocrinology*, 139, 552–561.
Stanley, T.L. et al. (2015). “Tesamoreline for treatment of HIV-associated lipodystrophy.” *Antiviral Therapy*, 20(5), 471–481.
Jansson, J.O. et al. (1985). “Growth hormone pulses and peripheral hormone homeostasis.” *Endocrine Reviews*, 6(2), 191–209.
Thuresson, J.D. et al. (2005). “Pharmacokinetics of CJC-1295, a long-acting GHRH analogue.” *Clinical Pharmacokinetics*, 44(5), 527–536.
CJC-1295 Complete Guide for Canadian Researchers